GET DAILY SIGNALSBoston Scientific (BSX) Posts Modest Q3 Sales Growth but Cuts Full-Year Guidance
Key Takeaways
- Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5% year over year on a reported, operational, and organic basis, narrowly above the consensus estimate of about $5.12 billion.
- Adjusted earnings per share (EPS) came in at $0.73, down 3% from $0.75 a year earlier and slightly below the roughly $0.75 analyst consensus.
- Net income under GAAP fell to $582 million, or $0.40 per diluted share, from $755 million, or $0.51, in the prior-year quarter.
- Management lowered its full-year 2026 outlook and guided fourth-quarter organic revenue to decline 1% to 3%, with adjusted EPS of $0.77 to $0.79.
- The August 2026 cybersecurity incident reduced quarterly organic growth by about 300 basis points and trimmed adjusted EPS by roughly $0.07.
Why This Quarter Matters
Boston Scientific has delivered strong growth in recent years, fueled by its electrophysiology and WATCHMAN businesses. This quarter represents a shift, as both areas faced rising competition and changing clinical data. The August cybersecurity incident added pressure, disrupting operations for about eight days and affecting sales and margins. In my view, the results test whether diversification can offset slowing momentum in two key high-growth segments. The reduced guidance also indicates management sees ongoing challenges into 2027, which makes this an important point to assess the longer-term outlook.
Breaking Down the Q3 Numbers
Boston Scientific reported net sales of $5.138 billion for the third quarter ended September 30, 2026, a 1.5% increase from $5.065 billion in the prior-year period. The result narrowly exceeded the consensus estimate of about $5.12 billion. Adjusted EPS of $0.73 declined 3% year over year and landed slightly below the approximately $0.75 analyst consensus, while GAAP net income attributable to common stockholders fell to $582 million, or $0.40 per diluted share.
By segment, Cardiovascular revenue rose 1.9% to $3.41 billion, while MedSurg revenue increased 0.6% to $1.73 billion. Within the portfolio, WATCHMAN sales declined 6% and electrophysiology sales fell 5%, reflecting softer left atrial appendage closure trends and pulsed field ablation share erosion. Management estimated the cybersecurity incident reduced organic revenue growth by roughly 300 basis points and adjusted EPS by about $0.07. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Responded
Shares of Boston Scientific fell sharply following the report, with the stock dropping as much as 8% in early trading before paring losses. The decline reflected investor disappointment over the earnings miss, the steep reduction in fourth-quarter and full-year guidance, and the acknowledgment that competition in electrophysiology and WATCHMAN has intensified. The market’s reaction showed that the headline revenue beat was outweighed by weaker profitability, margin contraction, and a cautious outlook. Sentiment heading into the print had already been cautious, and the combination of cyber-related disruption and lower forward expectations reinforced concerns that the company’s rapid growth phase has cooled.
What to Watch Going Forward
Boston Scientific guided fourth-quarter 2026 organic revenue to decline 1% to 3%, with adjusted EPS of $0.77 to $0.79, both below consensus. For the full year, the company now expects reported sales growth of about 4.25% and adjusted EPS of $3.16 to $3.18, down from its prior range of $3.28 to $3.32.
Looking ahead, management described 2027 as the trough of the current cycle and cautioned that revenue and adjusted EPS will be challenged to grow, excluding the pending Penumbra acquisition. Investors should monitor several catalysts: the timing of the FARAWAVE Ultra launch, now expected in early 2028; the ramp of the SEISMIQ intravascular lithotripsy platform; and the eventual close of the Penumbra deal, anticipated in early 2027.
Margin recovery will also be a key watch item as the company works through post-cyber manufacturing absorption issues and a restructuring program expected to generate more than $500 million in savings over three years. Pricing pressure in China adds another layer of uncertainty, but management expects these actions to support a return to stronger performance in 2028.
Refining Research with AI Tools
I often use Tickeron’s AI Screener to scan for comparable names and technical signals when reviewing earnings like these. It helps filter thousands of stocks by industry, patterns, and performance metrics, giving a structured way to surface ideas that align with my own criteria and saving time compared to manual checks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BSX's Indicator enters downward trend
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 129 similar instances where the Aroon Indicator formed such a pattern. In 85 of the 129 cases the stock moved lower. This puts the odds of a downward move at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 45%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 43 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
BSX moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Oscillator exited the oversold zone, 15 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for BSX just turned positive on October 12, 2026. Looking at past instances where BSX's MACD turned positive, the stock continued to rise in 27 of 44 cases over the following month. The odds of a continued upward trend are 61%.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 199 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.467) is normal, around the industry mean (3.824). P/E Ratio (17.040) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices
Advertisement